文献速递肥胖与代谢综合征

比较鲁塞尔Y形胃旁路术、可调节胃束带术与袖状胃切除术治疗重度肥胖:多中心、开放标签、三组随机对照试验

Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-03-31

By-Band-Sleeve 试验在12家英国医院纳入1346例重度肥胖成人,随机分配至鲁塞尔Y形胃旁路术、可调节胃束带术或袖状胃切除术,3年时胃旁路术和袖状胃切除术在减重和生存质量上优于胃束带术,胃旁路术最具有成本效益。

要点

  • 3年时达到≥50%多余体重下降的比例:胃旁路术组68%、胃束带术组25%、袖状胃切除术组41%。
  • EQ-5D效用评分均值:胃旁路术组0.72、胃束带术组0.62、袖状胃切除术组0.68。
  • 胃旁路术最具有成本效益;不推荐可调节胃束带术作为重度肥胖的标准治疗。

核心结论

  • 鲁塞尔Y形胃旁路术和袖状胃切除术比可调节胃束带术更有效;袖状胃切除术的减重效果和平均生存质量评分低于鲁塞尔Y形胃旁路术。
  • 基于该证据,推荐选择代谢和减重手术的患者接受鲁塞尔Y形胃旁路术;当有禁忌或不可行时,应提供袖状胃切除术。
  • 该证据不支持将可调节胃束带术作为重度肥胖的标准治疗。

研究设计与样本

  • By-Band-Sleeve 是一项在12家英国医院开展的实用、多中心、开放标签、随机对照试验。
  • 纳入标准为年龄≥18岁、符合国家代谢和减重手术标准的成人;初始为两组试验(胃旁路术 vs 胃束带术),在研究开始后2.6年因袖状胃切除术在英国广泛使用而改为三组试验。
  • 共同主要终点为3年时体重(达到≥50%多余体重下降的比例)和生存质量(EQ-5D效用评分)。
  • 2013年1月16日至2019年9月27日随机分配1351例参与者,5例撤回知情同意,最终纳入1346例(平均年龄47.3岁[SD 10.6],女性1020例[76%],男性324例[24%],2例数据缺失,平均体重129.7 kg[23.6],平均BMI 46.4 kg/m²[6.9])。
  • 1346例中,胃旁路术组462例(34%)、胃束带术组464例(34%)、袖状胃切除术组420例(31%);1183例(88%)接受了手术。

主要发现

  • 达到≥50%多余体重下降的比例:胃旁路术组276/405(68%),胃束带术组97/383(25%),袖状胃切除术组141/342(41%);校正风险差:胃旁路术 vs 胃束带术 41%(98% CI 34至48),袖状胃切除术 vs 胃束带术 15%(5至24),袖状胃切除术 vs 胃旁路术 -26%(-36至-16%)。
  • 平均EQ-5D评分:胃旁路术组0.72,胃束带术组0.62,袖状胃切除术组0.68;校正平均差:胃旁路术 vs 胃束带术 0.08(0.04至0.12),袖状胃切除术 vs 胃束带术 0.05(0.01至0.09),袖状胃切除术 vs 胃旁路术 -0.03(-0.07至0.01)。
  • 术后报告1651例不良事件;年发生率:袖状胃切除术5.7例/年,胃旁路术6.0例/年,可调节胃束带术4.6例/年。
  • 从随机化至3年共11例死亡:1例归因于手术(在可调节胃旁路术组,手术住院期间;原文此处写作可调节胃旁路术组,按上下文应为可调节胃束带术组),10例非归因于手术(胃旁路术组和胃束带术组各4例,袖状胃切除术组2例)。
  • 鲁塞尔Y形胃旁路术最具有成本效益。

关键数值与推荐

  • 非劣效界值:组间差异<12%。
  • 若达到≥50%多余体重下降的比例非劣效且生存质量更优,则袖状胃切除术和胃旁路术被认为比胃束带术更有效,袖状胃切除术比胃旁路术更有效。
  • 推荐选择代谢和减重手术的患者接受鲁塞尔Y形胃旁路术;当有禁忌或不可行时,应提供袖状胃切除术。
  • 该证据不支持可调节胃束带术作为重度肥胖的标准治疗。

临床怎么用

  • 基于该证据,推荐选择代谢和减重手术的患者接受鲁塞尔Y形胃旁路术;当有禁忌或不可行时,应提供袖状胃切除术。
  • 该证据不支持将可调节胃束带术作为重度肥胖的标准治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The health risks of severe obesity can be reduced with metabolic and bariatric surgery, but it is uncertain which operation is most effective or cost-effective. We aimed to compare Roux-en-Y gastric bypass, adjustable gastric banding, and sleeve gastrectomy in patients with severe obesity. METHODS: By-Band-Sleeve is a pragmatic, multi-centre, open-label, randomised controlled trial conducted in 12 hospitals in the UK. Eligible participants were adults (aged ≥18 years) meeting national criteria for metabolic and bariatric surgery. Initially, a 2-group trial (Roux-en-Y gastric bypass versus adjustable gastric banding) became a 3-group trial to include sleeve gastrectomy at 2·6 years from study opening, when it became widely used in the UK. Co-primary endpoints were weight (proportion achieving ≥50% excess weight loss) and quality-of-life (EQ-5D utility score) at 3 years. If the proportion achieving at least 50% excess weight loss was non-inferior (<12% difference between groups) and quality-of-life was superior, sleeve gastrectomy and Roux-en-Y gastric bypass were considered more effective than adjustable gastric banding, and sleeve gastrectomy more effective than Roux-en-Y gastric bypass. Cost-effectiveness of the procedures was compared. This trial is registered with ClinicalTrials.gov, NCT02841527, and ISRCTN, 00786323. RESULTS: Between Jan 16, 2013, and Sept 27, 2019, 1351 participants were randomly assigned; five withdrew consent and 1346 (mean age 47·3 [SD 10·6] years, 1020 [76%] women, 324 (24%) men, and two with missing data, mean weight of 129·7 kg [23·6] and mean BMI of 46·4 [6·9] kg/m2) were included in this report. Of 1346 participants, 462 (34%) were in the Roux-en-Y gastric bypass group, 464 (34%) in the adjustable gastric banding group, and 420 (31%) in the sleeve gastrectomy group. 1183 (88%) participants underwent surgery. 276 (68%) of 405 participants in the Roux-en-Y gastric bypass group, 97 (25%) of 383 participants in the adjustable gastric banding group and 141 (41%) of 342 participants in the sleeve gastrectomy group achieved at least 50% excess weight loss (adjusted risk difference: Roux-en-Y gastric bypass vs adjustable gastric banding 41% [98% CI 34 to 48]; sleeve gastrectomy vs adjustable gastric banding 15% [5 to 24]; sleeve gastrectomy vs Roux-en-Y gastric bypass, -26% [-36 to -16%]). Mean EQ-5D scores were 0·72 for Roux-en-Y gastric bypass, 0·62 for adjustable gastric banding, and 0·68 for sleeve gastrectomy (adjusted mean difference: Roux-en-Y gastric bypass vs adjustable gastric banding 0·08 [0·04 to 0·12], sleeve gastrectomy vs adjustable gastric banding 0·05 [0·01 to 0·09], and sleeve gastrectomy vs Roux-en-Y gastric bypass -0·03 [-0·07 to 0·01]). 1651 adverse events were reported following surgery (5·7 per year after sleeve gastrectomy, 6·0 per year after Roux-en-Y gastric bypass, and 4·6 per year after adjustable gastric banding). There were 11 deaths from randomisation to 3 years: one attributable to surgery (in the adjustable gastric bypass group, during the surgical admission) and ten not attributable to surgery (four each in the Roux-en-Y gastric bypass and adjustable gastric banding groups and two in the sleeve gastrectomy group). Roux-en-Y gastric bypass was most cost-effective. INTERPRETATION: Roux-en-Y gastric bypass and sleeve gastrectomy are more effective than adjustable gastric banding. Sleeve gastrectomy has inferior weight loss and lower mean quality of life score compared with Roux-en-Y gastric bypass. Based on this evidence, it is recommended that patients electing to have metabolic and bariatric surgery are advised to have Roux-en-Y gastric bypass. Where contraindicated or unfeasible, sleeve gastrectomy should be offered. This evidence does not support adjustable gastric band as standard treatment for severe obesity. FUNDING: National Institute for Health and Care Research Health Technology Assessment Programme.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025. PMID: 40179925. doi:10.1016/S2213-8587(25)00025-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。